General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Stocks Churn as Traders Waver on US Rates Outlook: Markets Wrap | news.google.com • |
Microsoft Stock Outlook: Is MSFT a Millionaire-Maker AI Play to Make? | news.google.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-15 | 2024-03 | -0.88 | -1.55 | -0.67 | -76.14% |
2024-02-14 | 2023-12 | -1 | -0.8 | 0.2 | 20.00% |
2023-12-22 | 2023-09 | -1 | -1 | N/A | N/A |
2023-08-14 | 2023-06 | -0.8 | -1.6 | -0.8 | -100.00% |
2023-05-15 | 2023-03 | -1.2 | -0.6 | 0.6 | 50.00% |
2023-02-14 | 2022-12 | -0.8 | -1.6 | -0.8 | -100.00% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-08-30 | Chardan Capital | Downgrade | Buy | Neutral |
2023-08-30 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
2023-08-29 | Brookline Capital | Downgrade | Buy | Hold |
2023-08-29 | Cantor Fitzgerald | Downgrade | Overweight | Neutral |
2023-08-29 | BTIG | Downgrade | Buy | Neutral |
2023-08-14 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2023-04-19 | DAGNON TERRY | Chief Operating Officer | 653.06K | Sale |
2024-03-06 | EVANSON JEFF | Officer | 808.46K | Purchase |
2024-03-27 | HADDADIN YEZAN MUNTHER | Director | 5.05K | Purchase |
2022-10-04 | HILZINGER KURT J | Director | 473.12K | Purchase |
2021-04-19 | KENYON LAWRENCE A. | Chief Executive Officer | 18.93K | Purchase |
2022-10-06 | SUKHTIAN FAISAL GHIATH | Director | 68.00K | Purchase |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Blackrock Inc. | 9.22M | 16.04M | 3.54% |
2023-06-29 | Vanguard Group Inc | 6.15M | 10.70M | 2.36% |
2023-06-29 | State Street Corporation | 2.75M | 4.79M | 1.06% |
2023-06-29 | Geode Capital Management, LLC | 2.72M | 4.73M | 1.05% |
2023-06-29 | Northern Trust Corporation | 1.26M | 2.18M | 0.48% |
2023-06-29 | Nuveen Asset Management, LLC | 598.96K | 1.04M | 0.23% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 3.61M | 6.28M | 1.39% |
2023-08-30 | iShares Russell 2000 ETF | 3.58M | 815.24K | 1.37% |
2023-06-29 | Vanguard Extended Market Index Fund | 1.45M | 2.52M | 0.56% |
2023-07-30 | Fidelity Small Cap Index Fund | 1.38M | 2.38M | 0.53% |
2023-08-30 | iShares Russell 2000 Growth ETF | 1.27M | 289.29K | 0.49% |
2023-05-30 | Fidelity Extended Market Index Fund | 519.75K | 779.62K | 0.20% |
Split | Date |
---|---|
1 : 20 | 2024-03-14 |
1 : 8 | 2019-03-18 |
Frank, do you have any evidence to back the B.S. that you post. No one here cares about your unfounded opinions.
Frank Chance the only sucker/clown at the table. We all know every penny OTLK goes up is a penny you lose. Do you have any education in finance or pharmaceuticals????
If the law suit is successful the lawyers will get millions. The investors will so little they will wish they didn’t waist their time. It is way to early to be thinking law suit. The current lawyer are ambulance chasers…. They may not be the best choice for representation…. When the time comes. Do keep in mind if they don’t get approved that you will have no case. If it doesn’t get approved there will be nothing there to sue for. This was always a big bet with the possibility of huge up side. You don’t lose until you sell. If you can’t ride it out then you shouldn’t have been here to start with. For full disclosure, I am long and believe it will be approved …. In time.
If you want to know why your outlook stock isn’t going up, call your broker and ask him to stop letting your shares. You are cutting your own throat by lending against yourself with a gluttony of shares on the market that don’t actually exist. It ONLY takes a phone call!
Lack of substantial evidence can be used in two forms by the FDA. First efficacy and safety of a new molecule second proving that the molecule can be produced in a safe and efficient manner meeting, safety, standards of efficacy, and quality. When the FDA inspected the facility, they did not do three checks of the product only one they also failed to clean the equipment properly. Thus, outlook was not able to show substantial evidence of its ability to produce the product. The FDA has use this term for this type of a problem for a very long time do your homework it’s easy to look up with multiples of examples.
Frank, who is the clown now? If what you said is true only a fool bets a $1.48 against a .12 cent gain. Why are you still here?
With the possibility of law suites, no one in their right mind is going to say anything but hard facts. If you are looking for predictions or hints you won’t find them at financial meetings. You can thank the lawyers for ambulance chasing early.
Lack of evidence could also mean that the manufacturer only did one test instead of three. Three is is what FDA require to endure product production quality. Hence, lack of evidence
There are just so many factual reasons to be long.Short have no science background and no understanding of the process. After 10 years of use and numerous studies with NIH and NEI. There is no one with a brain that thinks this won’t get to the finish line. This molecule has been used for this disease treatment for over a decade. Just stop and think and quit listening to the shorts. They are only here for their own selfish interests. The real money is long term!
Frank, looks like you got it wrong again.
Frank the question we all have is why are you still here. .21 a share is slumping even for you.
You have to laugh at shorts that post so much trash. Nothing but hot air to base their guesses on.
gooooooooo
5 shares lets go $OTLK
Is a good news or not?
Plz answer this question
$OTLK recommended oh Hold but the question Sale or not to Sale that a good question?!
I’m new to stockMaster app Can someone tell me how to follow other people?
Does anybody sense the presence of big dick energy. Just spread open & let it do the work. Buy the $10 calls $OTLK